Please note: The information displayed on this page might be outdated.
NMD Pharma ApS: Develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission.
Company Participants at Danish Science and The City DKBIO 17
- Claus Olesen, PhD, CBO
- Thomas Pedersen, CEO